A Product overview with focus on Rare Diseases.
AOP Orphan's focus is on Rare Diseases. The portfolio comprises products in the following therapeutic areas: HematoOncology, Cardiology & Pulmonology, Neurology and Metabolic Disorders. AOP Orphan’s strategic goal is to constantly deliver new treatment options with respect to Rare Diseases.
Adasuve® is indicated for the rapid control of mild-to-moderate agitation (increased, unproductive physical activity coupled with internal tension) in adult patients with schizophrenia or biopolar disorder. Patients should receive regular treatment immediately after control of acute agitation symptoms.
Anagrelide AOP is indicated for the reduction of elevated platelet counts and associated clinical symptoms in at high risk essential thrombocythemia patients.
Artesyd® is used at Hyperkinetic motor disorders with Huntington’s chorea and the treatment of moderate to severe tardive dyskinesia.
Busilvex® is a concentrate used to conditioning treatment prior to stem cell transplantation. Pierre Fabre is the MA-Holder and AOP Orphan has the distribution right.
Canemes® contains the active ingredient nabilone, a synthetically produced substance belonging to a group of compounds called cannabinoids (derived from cannabis plant). Canemes® prevents nausea and vomiting in patients undergoing chemotherapy for malignant tumours and is used if other drugs do not have the desired effect.
Dystardis® is used for the treatment of diseases causing jerky, irregular, uncontrollable movements, hyperkinetic motor disorders with Huntington's chorea.
Empressin® is used for the treatment of catecholamine refractory hypotension following septic shock in patients older than 18 years. A catecholamine refractory hypotension is present if the mean arterial blood pressur cannot be stabilized to 65 – 75 mmHg despite adequate volume substitution and application of catecholamines.
Esmocard® is indicated for supraventricular tachycardia and for the rapid control of the ventricular rate in patients with atrial fibrillation or atrial flutter in perioperative, postoperative, or other circumstances where short-term control of the ventricular rate with a short-acting agent is desirable.
Esmolol is indicated for supraventricular tachycardia and for the rapid control of the ventricular rate in patients with atrial fibrillation or atrial flutter in perioperative, postoperative, or other circumstances where short-term control of the ventricular rate with a short-acting agent is desirable.
Feraccru® is indicated for adults for the treatment of iron deficiency.
Motetis is used as symptomatic therapy in the treatment of hyperkinetic motor disorders in Huntington’s disease. Tetrabenazine is also used in etiologist such as tardive dyskinesia, tics and dystonia.
Naloxone hydrochloride is for complete or partial reversal of CNS and especially respiratory depression, caused by natural or synthetic opioids.
Ocaliva® is indicated for the treatment of primary biliary cholangitis (also known to as primary biliary cirrhosis) in combination with ursodeoxycholic acid (UDCA) in adults with an inadequate response to UDCA or as monotherapy in adults unable to tolerate UDCA.
Ospolot® is an antiepileptic drug and is used to treat Rolandic epilepsy.
Remodulin® is used to treat idiopathic or hereditary pulmonary arterial hypertension (PAH) in patients with medium to severe symptoms.
Tardiben® tablets are indicated for both hyperkinetic motor disorders associated with Huntington’s chorea and the treatment of moderate to severe tardive dyskinesia, which is an adverse effect associated with antipsychotic medicines.
Tetmodis® is used as symptomatic therapy in the treatment of hyperkinetic motor disorders in Huntington’s disease. Tetrabenazine is also used in etiologies such as tardive dyskinesia, tics and dystonia.
Tetrabenazine is used as symptomatic therapy in the treatment of hyperkinetic motor disorders in Huntington’s disease. Tetrabenazine is also used in aetiology such as tardive dyskinesia, tics and dystonia.
Thromboreductin® is indicated for the reduction of elevated platelet counts and associated clinical symptoms in at high risk essential thrombocythemia patients
Wakix® is indicated in adults for the treatment of narcolepsy with or without cataplexy.
Yal® is used for the colon & rectal cleansing preparation before operations.